Acasti Pharma Inc - Ordinary Shares - Class A
ACST
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.17M
Close$
$1.74
48.4% downside
Current Fair Value
48.4% downsideOvervalued by 48.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.17 Million |
|---|---|
| Enterprise Value | $20.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.47 |
| Beta | 1.52 |
| Outstanding Shares | 17,269,986 |
Return
| Return on Equity | -45.47% |
|---|---|
| Return on Assets | -43.78% |
| Return on Invested Capital | -11.51% |
Valuation & Multiples
| P/E Ratio | -1.66 |
|---|---|
| PEG | -0.45 |
| Price to Sales | - |
| Price to Book Ratio | 1.69 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Acasti Pharma Inc
5 employees
CEO: Janelle D'Alvise Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental trea...